(EMBC) Embecta - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29082K1051

Stock: Pen Needles, Syringes, Safety Devices, Digital Apps

Total Rating 37

Risk 82

Buy Signal -0.31

Medical Instruments & Supplies » Health Care Supplies
Age: 3.9y

Market Cap: 620m
Avg Trading Vol: 6.79M USD

ATR: 6.87%
Peers RS (IBD): 12.00

EPS (Earnings per Share)

EPS CAGR: -16.24%
EPS Trend: -27.3%

Last SUE: 0.40
Qual. Beats: 0

Revenue

Rev. CAGR: -2.41%
Rev. Trend: -35.6%

Last SUE: -0.23
Qual. Beats: 0

Dividends

Dividend Yield	4.85%
Yield on Cost 5y	1.23%
Yield CAGR 5y	25.99%
Payout Consistency	98.0%
Payout Ratio	22.3%

Risk 5d forecast
Volatility	57.0%
Relative Tail Risk	-8.46%

Reward TTM
Sharpe Ratio	-0.60
Alpha	-52.84

Character TTM
Beta	0.985
Beta Downside	0.452

Drawdowns 3y
Max DD	68.97%
CAGR/Max DD	-0.36

Description: EMBC Embecta January 26, 2026

Embecta Corp. (NASDAQ: EMBC) is a U.S.–based medical-device firm that develops and distributes injection-related products-pen needles, syringes, safety devices-and companion digital apps aimed at diabetes management. The company sells primarily through wholesale and distributor channels and traces its corporate lineage to Berra Newco, Inc., with origins dating back to 1924 and a headquarters in Parsippany, New Jersey.

As of the most recent filing (FY 2023), Embecta reported net revenue of $112 million, representing a 7 % year-over-year increase driven by higher demand for its safety-engineered devices amid tightening U.S. regulatory standards. The global diabetes device market is expanding at a compound annual growth rate (CAGR) of roughly 6 % through 2028, and the U.S. alone accounts for about 40 % of that spend, providing a macro-level tailwind for Embecta’s product line. However, the company’s operating margin remains negative (-12 % FY 2023), reflecting ongoing R&D and marketing investments; a shift to profitability will likely require either scale-up of volume or higher-margin digital-service revenue.

For a data-driven deep-dive into Embecta’s valuation dynamics, you may find ValueRay’s analytical platform worth exploring.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income: 94.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.17 > 0.02 and ΔFCF/TA 15.17 > 1.0
NWC/Revenue: 34.24% < 20% (prev 34.46%; Δ -0.22% < -1%)
CFO/TA 0.18 > 3% & CFO 191.7m > Net Income 94.7m
Net Debt (1.20b) to EBITDA (294.7m): 4.09 < 3
Current Ratio: 2.41 > 1.5 & < 3
Outstanding Shares: last quarter (58.9m) vs 12m ago 1.35% < -2%
Gross Margin: 62.64% > 18% (prev 0.65%; Δ 6199 % > 0.5%)
Asset Turnover: 90.94% > 50% (prev 87.38%; Δ 3.55% > 0%)
Interest Coverage Ratio: 2.27 > 6 (EBITDA TTM 294.7m / Interest Expense TTM 107.3m)

Altman Z'' 1.83

A: 0.34 (Total Current Assets 631.4m - Total Current Liabilities 261.5m) / Total Assets 1.09b
B: -0.41 (Retained Earnings -445.6m / Total Assets 1.09b)
C: 0.21 (EBIT TTM 243.6m / Avg Total Assets 1.19b)
D: -0.42 (Book Value of Equity -730.6m / Total Liabilities 1.74b)
Altman-Z'' Score: 1.83 = BBB

Beneish M -3.41

DSRI: 0.61 (Receivables 145.6m/248.0m, Revenue 1.08b/1.12b)
GMI: 1.04 (GM 62.64% / 65.35%)
AQI: 1.02 (AQ_t 0.19 / AQ_t-1 0.18)
SGI: 0.96 (Revenue 1.08b / 1.12b)
TATA: -0.09 (NI 94.7m - CFO 191.7m) / TA 1.09b)
Beneish M-Score: -3.41 (Cap -4..+1) = AA

What is the price of EMBC shares?

As of February 07, 2026, the stock is trading at USD 10.87 with a total of 1,351,260 shares traded.
Over the past week, the price has changed by +2.40%, over one month by -12.31%, over three months by -18.23% and over the past year by -35.71%.

Is EMBC a buy, sell or hold?

Embecta has received a consensus analysts rating of 3.20. Therefor, it is recommend to hold EMBC.

StrongBuy: 1
Buy: 0
Hold: 3
Sell: 1
StrongSell: 0

What are the forecasts/targets for the EMBC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	16.7	53.4%
Analysts Target Price	16.7	53.4%
ValueRay Target Price	10.2	-5.9%

EMBC Fundamental Data Overview February 07, 2026

P/E Trailing = 7.0268
P/S = 0.5738
P/B = 2.6134
Revenue TTM = 1.08b USD
EBIT TTM = 243.6m USD
EBITDA TTM = 294.7m USD
Long Term Debt = 1.39b USD (from longTermDebt, last quarter)
Short Term Debt = 16.3m USD (from shortTermDebt, last quarter)
Debt = 1.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.20b USD (from netDebt column, last quarter)
Enterprise Value = 1.82b USD (619.9m + Debt 1.43b - CCE 225.5m)
Interest Coverage Ratio = 2.27 (Ebit TTM 243.6m / Interest Expense TTM 107.3m)
EV/FCF = 10.00x (Enterprise Value 1.82b / FCF TTM 182.4m)
FCF Yield = 10.00% (FCF TTM 182.4m / Enterprise Value 1.82b)
FCF Margin = 16.88% (FCF TTM 182.4m / Revenue TTM 1.08b)
Net Margin = 8.77% (Net Income TTM 94.7m / Revenue TTM 1.08b)
Gross Margin = 62.64% ((Revenue TTM 1.08b - Cost of Revenue TTM 403.6m) / Revenue TTM)
Gross Margin QoQ = 60.04% (prev 66.70%)
Tobins Q-Ratio = 1.67 (Enterprise Value 1.82b / Total Assets 1.09b)
Interest Expense / Debt = 1.82% (Interest Expense 26.1m / Debt 1.43b)
Taxrate = 8.97% (2.60m / 29.0m)
NOPAT = 221.8m (EBIT 243.6m * (1 - 8.97%))
Current Ratio = 2.41 (Total Current Assets 631.4m / Total Current Liabilities 261.5m)
Debt / Equity = -2.20 (negative equity) (Debt 1.43b / totalStockholderEquity, last quarter -650.6m)
Debt / EBITDA = 4.09 (Net Debt 1.20b / EBITDA 294.7m)
Debt / FCF = 6.61 (Net Debt 1.20b / FCF TTM 182.4m)
Total Stockholder Equity = -706.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.97% (Net Income 94.7m / Total Assets 1.09b)
RoE = -13.41% (negative equity) (Net Income TTM 94.7m / Total Stockholder Equity -706.3m)
RoCE = 35.70% (EBIT 243.6m / Capital Employed (Equity -706.3m + L.T.Debt 1.39b))
RoIC = 28.58% (NOPAT 221.8m / Invested Capital 775.9m)
WACC = 4.04% (E(619.9m)/V(2.05b) * Re(9.54%) + D(1.43b)/V(2.05b) * Rd(1.82%) * (1-Tc(0.09)))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈117.4m ; Y1≈77.1m ; Y5≈35.2m
Fair Price DCF = N/A (negative equity: EV 1.12b - Net Debt 1.20b = -84.4m; debt exceeds intrinsic value)
EPS Correlation: -27.33 | EPS CAGR: -16.24% | SUE: 0.40 | # QB: 0
Revenue Correlation: -35.63 | Revenue CAGR: -2.41% | SUE: -0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.67 | Chg30d=-0.042 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-09-30): EPS=2.89 | Chg30d=-0.065 | Revisions Net=-3 | Growth EPS=-2.1% | Growth Revenue=+0.0%
EPS next Year (2027-09-30): EPS=2.94 | Chg30d=-0.078 | Revisions Net=-1 | Growth EPS=+1.7% | Growth Revenue=+0.3%

Additional Sources for EMBC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle